KZIA

Kazia Therapeutics Limited NASDAQ Listed Jan 6, 1999

Healthcare ·Biotechnology ·AU · kaziatherapeutics.com

$13.41

Mkt Cap $21.7M

52w Low $3.05 72.2% of range 52w High $17.40

50d MA $9.35 200d MA $8.22

P/E (TTM) -0.7x

EV/EBITDA -0.5x

P/B —

Debt/Equity -0.1x

ROE —

P/FCF -0.8x

RSI (14) —

ATR (14) —

Beta 1.62

50d MA $9.35

200d MA $8.22

Avg Volume 203.7K

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

SIC Code

2834

CIK (SEC)

1075880

Phone

1300 787 272

Three International Towers · Sydney, NSW 2000 · AU

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-0.01	-0.41	-5760.4%	8.11	+2.3%	-7.2%	-0.3%	+5.3%	-5.4%	-4.8%	—
Jun 30, 2025	AMC	-0.01	-4.18	-9999.0%	6.27	-2.6%	+5.7%	-0.8%	+2.6%	-3.0%	+4.3%	—
May 28, 2025	AMC	-10.76	-7.61	+29.3%	3.56	-0.3%	+6.2%	+0.5%	-0.5%	+26.7%	+11.9%	—
Nov 19, 2024	AMC	-15.00	-20.81	-38.8%	28.55	-0.7%	-1.8%	-1.4%	+4.2%	-4.7%	+1.6%	—
Mar 27, 2024	AMC	—	-12.53	—	15.69	-7.6%	-1.3%	+4.9%	+1.4%	+2.2%	-1.1%	—
Nov 27, 2023	AMC	-1.66	-10.02	-504.8%	29.90	+10.4%	+7.0%	-6.3%	-6.4%	-19.6%	-0.7%	—
Mar 9, 2023	AMC	-24.65	-31.86	-29.3%	50.88	-0.7%	-1.7%	-2.0%	+3.1%	-7.0%	+3.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jan 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.15	$7.16	+0.1%	-8.3%	-7.0%	-3.9%	+5.8%	-2.3%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.08	$13.54	+3.5%	-20.3%	-8.8%	+5.0%	-8.8%	+9.6%
Oct 2	Maxim Group	Maintains	Buy → Buy	—	$6.85	$6.84	-0.1%	-7.9%	+4.0%	+3.4%	+5.3%	+0.3%
Jul 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.53	$8.90	-6.6%	+8.7%	+4.2%	+5.8%	-5.5%	-5.6%
Jun 11	Maxim Group	Maintains	Buy → Buy	—	$5.26	$10.50	+99.6%	+81.4%	+2.6%	-5.0%	-2.7%	+3.1%
Jul 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$62.00	$53.50	-13.7%	-27.8%	-37.7%	+2.6%	+15.1%	-9.9%
Apr 11	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$54.50	$57.50	+5.5%	+6.4%	+2.6%	+1.7%	+9.1%	+2.3%
Aug 2	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$96.00	$91.00	-5.2%	-2.6%	-5.9%	+0.9%	+4.8%	-3.2%
Aug 2	Maxim Group	Downgrade	Buy → Hold	—	$96.00	$91.00	-5.2%	-2.6%	-5.9%	+0.9%	+4.8%	-3.2%
Oct 14	Maxim Group	Maintains	Buy → Buy	—	$535.50	$555.50	+3.7%	-1.9%	-0.1%	-0.2%	+3.0%	-0.9%
Jan 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$449.00	$490.00	+9.1%	+7.7%	-4.4%	+5.7%	+2.3%	+3.0%

Data updated apr 26, 2026 11:18am · Source: massive.com